Overview

Is Saxenda® a Viable Treatment of Obese Patients in Forensic Psychiatry?

Status:
Not yet recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
An open-label, multi-centre, 26-weeks clinical feasibility study. The objective is to explore whether Saxenda could be a feasible choice in the treatment of overweight, obesity and weight-related medical problems, in patients diagnosed with a severe mental illness and hospitalized at a forensic department in Denmark. We wish to determine the viability of the daily Saxenda®-injection treatment in this specific patient group.
Phase:
Phase 4
Details
Lead Sponsor:
Anders Fink-Jensen, MD, DMSci
Treatments:
Liraglutide